Prognostic role of PIK3CA and co-alterations in advanced biliary tract cancer: A multicenter retrospective analysis.
Oluseyi Abidoye(Mayo Clinic), Tanios S. Bekaii-Saab(WinnMed), Chigusa Morizane(Tokyo National Hospital), T. Yoshino(National Cancer Center Hospital East), Taro Shibuki(National Cancer Center Hospital East), Mitesh J. Borad(Jacksonville College), Heidi Kosiorek(Mayo Clinic in Florida), Y. Nakamura(National Cancer Center Hospital East), John Strickler(Duke Medical Center), Pedro Luiz Serrano Usón(Hospital Israelita Albert Einstein), Hideaki Bando(National Cancer Center Hospital East), Mohamad Bassam Sonbol(WinnMed), Mitsuho Imai(National Cancer Center Hospital East), Daniel H. Ahn(WinnMed), Christina Wu(WinnMed), Maria Fernanda Botelho Teixeira(Hospital Israelita Albert Einstein), Masafumi Ikeda(National Cancer Center Hospital East), Takao Fujisawa(National Cancer Center Hospital East), Angelo Pirozzi(Humanitas University)
Cited by 0
Related Papers
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
|Cell Reports|2017|619
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423